Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01042158 · ClinicalTrials.gov registry record · Phase 4
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
A Phase 4 study of Pulmonary Hypertension and Pulmonary Arterial Hypertension, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT01042158 is a Phase 4 study of Pulmonary Hypertension and Pulmonary Arterial Hypertension that has completed, run by Johns Hopkins University. The registered enrollment target is 25 participants, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01042158, a Phase 4 study of Pulmonary Hypertension and Pulmonary Arterial Hypertension, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This will be a 36-week, single group, open label study assessing the effects of Tadalafil plus Ambrisentan combination therapy in patients with pulmonary arterial hypertension associated with the scleroderma spectrum of disease (PAH-SSD). Standard outcome measures such as six-minute walk distance (6MWD), New York heart Association (NYHA) classification, and hemodynamic measurements will be assessed, as well as novel functional measures of RV-PV function including the transthoracic echocardiogram parameter tricuspid annular plane systolic ejection (TAPSE), contrast-enhanced cardiac MRI and heart rate variability assessed by Holter monitoring. This design (excluding a placebo arm) was selected for ethical concerns and to provide optimal efficiency and active therapy to all study subjects. It also allows for comparisons between the two monotherapies and with combination therapy.
Conditions Studied
Interventions
- DRUG tadalafil and ambrisentan upfront combination therapy
Study Locations (1)
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01042158
The ClinicalTrials.gov registry entry for NCT01042158 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (96% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 1 intervention - of which tadalafil and ambrisentan upfront combination therapy is the first listed.
NCT01042158 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01042158 about?
NCT01042158 is a clinical study titled "A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis". This will be a 36-week, single group, open label study assessing the effects of Tadalafil plus Ambrisentan combination therapy in patients with pulmonary arterial hypertension associated with the scleroderma spectrum of disease (PAH-SSD). Standard outcome measures such as six-minute walk distance (6...
What is the current status of trial NCT01042158?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2010-01. Estimated completion is 2014-11.
What conditions does trial NCT01042158 study?
This clinical trial studies the following conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension, Systemic Sclerosis, Connective Tissue Disease, Scleroderma Spectrum of Diseases.
What interventions are being tested in trial NCT01042158?
The interventions under investigation include: tadalafil and ambrisentan upfront combination therapy (DRUG).
Who is sponsoring clinical trial NCT01042158?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01042158 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE
ACTIVE NOT RECRUITING · Phase 4
-
Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction
COMPLETED · Phase 4
-
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan
COMPLETED · Phase 4
-
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
RECRUITING
-
Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope
RECRUITING
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.